Grifols, S.A.

GRF

ES0171996087

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 09:21:30 2024-06-12 EDT			5-day change	1st Jan Change
9.374 ^EUR	+3.95%		-1.03%	-39.05%

06-10	European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading	MT
06-07	European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	MT

Grifols' current CEO to become non-executive chairman in 2025

February 29, 2024 at 09:00 am

Current CEO and executive chairman of Spanish drugmaker Grifols Thomas Glanzmann, who will step down as CEO and remain executive chairman on April 1, said Thursday he will become non-executive chairman of the company in 2025.

(Reporting by Joan Faus; writing by David Latona; edited in Spanish by Javi West Larrañaga)

Go to the original article.
Legal disclaimer

Latest news about Grifols, S.A.

European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading	06-10	MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	06-07	MT
Grifols, S.A. Reports the Successful Closing of the Private Placement of Additional 7.5% Senior Secured Notes Due 2030	06-04	CI
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading	06-03	MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading	05-29	MT
Solaria expects energy prices to rise this year	05-28	RE
Solaria sees higher energy prices later this year, shares rise	05-27	RE
Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	05-23	MT
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	05-22	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	05-17	MT
GRIFOLS : In line Q1 and on track deleveraging; worth a go	05-15
Grifols, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Grifols swings to first-quarter profit, says guidance on track	05-14	RE
Grifols' CFO Alfredo Arroyo Will Leave Company Next Year	05-14	RE
GRIFOLS' CFO ALFREDO ARROYO WILL LEAVE COMPANY NEXT Y…	05-14	RE
Grifols posts first-quarter profit of 21 million euros	05-14	RE
GRIFOLS CEO SAYS CAN CONFIRM SHANGHAI RAAS TRANSACTION WILL CLO…	05-14	RE
Transcript : Grifols, S.A., Q1 2024 Earnings Call, May 14, 2024	05-14
Spain's Grifols swings to first-quarter profit of 21 mln euros	05-14	RE
Grifols shares fall after new Gotham City Research report	05-14	RE
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher	05-13	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	05-09	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading	05-08	MT
Sector Update: Health Care Stocks Advance in Monday Afternoon Trading	05-06	MT
Grifols Shares Rise as Haier Deal Set to Close in June	05-06	MT

Chart Grifols, S.A.

Duration

Period

More charts

Company Profile

Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.1%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).

Sector

Pharmaceuticals

Calendar

2024-07-24 - Q2 2024 Earnings Release (Projected)

Related indices

STOXX EUROPE 600 (EUR) , IBEX 35

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

GRIFOLS : In line Q1 and on track deleveraging; worth a go

May 15, 2024 at 07:54 am

Gotham City sets its sights on Grifols

January 09, 2024 at 10:09 am

More Strategies

Ratings for Grifols, S.A.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

9.018 EUR

Average target price

17.35 EUR

Spread / Average Target

+92.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
GRIFOLS, S.A.	-39.05%	5.87B
CSL LIMITED	-1.54%	91.26B
SAMSUNG BIOLOGICS CO.,LTD.	-2.63%	38.17B
UCB	+70.28%	26.74B
BIOMARIN PHARMACEUTICAL INC.	-13.02%	15.93B
INCYTE CORPORATION	-5.27%	13.37B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-10.50%	11.77B
ALTEOGEN INC.	+187.82%	10.92B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-49.11%	10.27B
SWEDISH ORPHAN BIOVITRUM AB	-0.37%	8.69B

Biopharmaceuticals

Grifols, S.A.

Equities

GRF

ES0171996087

Pharmaceuticals

Grifols' current CEO to become non-executive chairman in 2025

EPS Revisions